Drug · CHEMBL810

TEMOZOLOMIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. TEMOZOLOMIDE. Drugs and targets, record CHEMBL810. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL810

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: TEMOZOLOMIDE; ChEMBL
ChEMBL ID: CHEMBL810; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Temodal, Temodar, Temomedac, Temozolomide accord, Temozolomide hexal, Temozolomide sandoz, Temozolomide sun, Temozolomide teva; ChEMBL
Other names: CCRG-81045, M&B 39831, M&B-39831, M-39831, Methazolastone, Mk-7365, NSC-362856, SCH 52365, SCH-52365, Temozolomida; ChEMBL
DrugBank: DB00853; DrugBank
InChIKey: BPEGJWRSRHCHSN-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 122 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases122

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
glioblastoma	Approval	DailyMed and TTD	425	423	https://conductscience.org/library/drugs?q=MONDO_0018177
malignant glioma	Approval	PMDA	81	80	https://conductscience.org/library/drugs?q=MONDO_0100342
melanoma	Phase 3	ClinicalTrials.gov	72	72	https://conductscience.org/library/drugs?q=MONDO_0005105
glioma	Approval	EMA Human Drugs	55	48	https://conductscience.org/library/drugs?q=MONDO_0021042
neuroblastoma	Phase 3	ClinicalTrials.gov	42	41	https://conductscience.org/library/drugs?q=MONDO_0005072
gliosarcoma	Phase 3	ClinicalTrials.gov	38	38	https://conductscience.org/library/drugs?q=MONDO_0016681
primary central nervous system lymphoma	Phase 3	ClinicalTrials.gov	26	26	https://conductscience.org/library/drugs?q=MONDO_0002571
anaplastic astrocytoma	Phase 3	ClinicalTrials.gov	25	25	https://conductscience.org/library/drugs?q=MONDO_0016684
Ewing sarcoma	Phase 3	ClinicalTrials.gov	24	24	https://conductscience.org/library/drugs?q=MONDO_0012817
small cell lung carcinoma	Phase 2/3	ClinicalTrials.gov	19	19	https://conductscience.org/library/drugs?q=MONDO_0008433

1 to 10 of 122Source Open Targets

See all 122 diseases

Trials986

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00304031	Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma	Phase 3	1,173	2014-04-30	temozolomide	Its name	ClinicalTrials.gov
NCT00943826	A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma	Phase 3	921	2013-05-20	temozolomide	Its name	ClinicalTrials.gov
NCT00091572	Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)	Phase 3	859	2009-03-12	temozolomide	Its name	ClinicalTrials.gov
NCT00626990	Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)	Phase 3	751	2023-09-11	temozolomide	Its name	ClinicalTrials.gov
NCT03345095	A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma	Phase 3	749	2024-01-31	temozolomide	Its name	ClinicalTrials.gov
NCT02667587	An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)	Phase 3	716	2022-02-03	temozolomide	Its name	ClinicalTrials.gov
NCT00884741	Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma	Phase 3	637	2016-10-12	temozolomide	Its name	ClinicalTrials.gov
NCT00482677	Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme	Phase 3	562	2018-01-23	temozolomide	Its name	ClinicalTrials.gov
NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)	Phase 3	560	2021-02-03	temozolomide	Its name	ClinicalTrials.gov
NCT01704287	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)	Phase 2	540	2017-03-28	temozolomide	Its name	ClinicalTrials.gov

1 to 10 of 986

See all 986 trials

Comparisons in its trials135

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Bevacizumab + RT+Temozolomide vs Placebo + RT+Temozolomide: serious adverse events	179 of 461	115 of 450	911	NCT00943826	Trial comparisons
Temozolomide vs Dacarbazine: serious adverse events	124 of 419	100 of 421	840	NCT00091572	Trial comparisons
Radiotherapy, Temozolomide Plus Nivolumab vs Radiotherapy, Temozolomide Plus Placebo: deaths from any cause	263 of 358	255 of 358	716	NCT02667587	Trial comparisons
Radiotherapy, Temozolomide Plus Nivolumab vs Radiotherapy, Temozolomide Plus Placebo: serious adverse events	259 of 355	217 of 354	709	NCT02667587	Trial comparisons
Experimental Arm vs Standard Arm: deaths from any cause	55 of 309	57 of 307	616	NCT03345095	Trial comparisons
Randomized Arm 1: TMZ+RT + Placebo vs Randomized Arm 2: TMZ+RT + Bevacizumab: Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0	87 of 300	97 of 303	603	NCT00884741	Trial comparisons
Experimental Arm vs Standard Arm: serious adverse events	114 of 305	80 of 297	602	NCT03345095	Trial comparisons
Nivolumab + Radiation Therapy vs Temozolomide + Radiation Therapy: deaths from any cause	269 of 280	253 of 280	560	NCT02617589	Trial comparisons
Nivolumab + Radiation Therapy vs Temozolomide + Radiation Therapy: serious adverse events	206 of 278	141 of 275	553	NCT02617589	Trial comparisons
Temozolomide vs Radiation: serious adverse events	158 of 271	135 of 271	542	NCT00482677	Trial comparisons

1 to 10 of 135

See all 135 comparisons in its trials

Papers from its trials496

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41980234	RESULT	1	PubMed
41249450	RESULT	1	PubMed
39882966	RESULT	1	PubMed
39594133	RESULT	1	PubMed
38946878	RESULT	1	PubMed
37861218	RESULT	1	PubMed
37249604	RESULT	1	PubMed
37142373	RESULT	1	PubMed
37060055	RESULT	1	PubMed
36894288	RESULT	1	PubMed

1 to 10 of 496

See all 496 papers from its trials

Tests in its trials11

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Verbal Fluency	16	3	ConductCognition
Trail Making Test A	15	2	ConductCognition
Verbal Learning	14	2	ConductCognition
Trail Making Test B	13	1	ConductCognition
Digit Span Test	2	0	ConductCognition
Clock Drawing Task	1	0	ConductCognition
Continuous Performance Test	1	0	ConductCognition
Finger Tapping Task	1	0	ConductCognition
Stroop Color-Word Test	1	0	ConductCognition
Symbol Coding	1	0	ConductCognition

1 to 10 of 11

See all 11 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL810

GET https://conductscience.org/api/drugs/v1/CHEMBL810/diseases?page=2

API reference For AI assistants